White House bats down speculation that Trump got access to Eli Lilly obesity drug for ‘compassionate use’

The White House has firmly denied claims that President Trump received access to the experimental weight-loss drug retatrutide from Eli Lilly through the FDA's "compassionate use" program. This speculation arose amid concerns about the drug's potential benefits and the ethics of access to unapproved medications. The denial is significant as it counters rumors that could influence public perception and trust in both the administration and pharmaceutical regulatory processes. This move underscores the importance of maintaining transparency in the distribution of experimental drugs.